Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases. 

IARC’s Mission: Cancer research for cancer prevention The International Agency for Research on Cancer (IARC) is the specialized cancer agency of the World Health Organization. The objective of the IARC is to promote international collaboration in cancer research. The Agency is inter-disciplinary, bringing together skills in epidemiology, laboratory sciences and biostatistics to identify the causes of cancer so that preventive measures may be adopted and the burden of disease and associated suffering reduced. A significant feature of the IARC is its expertise in coordinating research across countries and organizations; its independent role as an international organization facilitates this activity. The Agency has a particular interest in conducting research in low and middle-income countries through partnerships and collaborations with researchers in these regions. Causes and prevention of cancer Emphasis is placed on elucidating the role of environmental and lifestyle risk factors and studying their interplay with genetic background in population-based studies and appropriate experimental models. This emphasis reflects the understanding that most cancers are, directly or indirectly, linked to environmental factors and thus are preventable. The IARC Monographs Programme is a core element of the Agency’s portfolio of activities, with international expert working groups evaluating the evidence of the carcinogenicity of specific exposures. The Agency is also committed to studying approaches for the early detection of cancer and in evaluating prevention strategies. A global reference for cancer information The IARC has an important role in describing the burden of cancer worldwide, through co-operation with and assistance to cancer registries and in monitoring geographical variations and trends over time. Key publications include the Cancer Incidence in Five Continents series and GLOBOCAN. The classification of human tumours as reported in the WHO “Blue Book” series is an additional resource of value to cancer researchers and clinicians worldwide. In all cases the Agency strives to make its findings available to the widest possible audience. Global cancer biobank One of the products of IARC’s coordinating role is an increasingly important biobank with currently approximately 6 million samples from 600 000 subjects in total. This resource permits the application of innovative laboratory-based methodologies to study the causes, early detection and prevention of cancer through collaborative studies with many international partners. Education and training A core part of the Agency’s mission is education and training of cancer researchers worldwide. This is achieved through fellowships, courses and publications. Priority is given to training researchers from low and middle-income countries in the areas of cancer epidemiology and cancer registration. Producing evidence-based science for global cancer control policies The close working relationship between IARC and its parent organization, WHO, allows the research findings of the Agency to be translated effectively into timely policies for cancer control. This is manifest, for example, in co-operation in terms of reduction in tobacco use, implementation of vaccination against viruses associated with cancer causation, or in assessing the effectiveness of intervention strategies. IARC is not involved directly in implementation of control measures, nor does it conduct research on treatment or care of cancer patients.

The IAEA’s aim is to help build Member States’ capacities to support them in establishing high-quality health care worldwide. Nuclear technology plays a key role in the diagnosis and treatment of cancer. Over the past six decades, the IAEA has gained strong technical expertise and experience in the delivery of nuclear medicine and radiotherapy technology to Member States, contributing to the fight against cancer. Its support ranges from nutrition interventions, cancer diagnosis and treatment, quality assurance for the use of radiation in medicine for safe and accurate treatment of conditions such as cancer. The IAEA also assists Member States with the coordination of research projects, expert guidance, imPACT Reviews, resource mobilization, the development of internationally harmonized guidelines and supporting the development of strategic documents, training, and knowledge exchange, safety and quality.

Founded in 1948, WHO is the United Nations agency that connects nations, partners and people to promote health, keep the world safe and serve the vulnerable – so everyone, everywhere can attain the highest level of health. WHO leads global efforts to expand universal health coverage. We direct and coordinate the world’s response to health emergencies. And we promote healthier lives – from pregnancy care through old age. Our Triple Billion targets outline an ambitious plan for the world to achieve good health for all using science-based policies and programmes.

Exact Sciences, now Abbott, is a leading provider of cancer screening and diagnostic tests. From hereditary cancer risk and early detection to treatment guidance and therapy selection, our products aim to support patients before, during, and after diagnosis. For more information, visit https://www.abbott.com/en-us/exact-sciences 

Founded by Unitaid in 2010, the Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, innovative medicines and other health technologies for people in need in low- and middle-income countries. We work at the intersection of innovation, manufacturing and public health, partnering with civil society, governments, pharmaceutical companies, and international organisations. By bringing these actors together, MPP helps translate medical innovation into real-world access and impact, across countries and disease areas. Through public health-oriented voluntary licensing and technology transfer, MPP works with innovators and manufacturers to enable the development, production and scale-up of quality-assured medicines and health technologies in countries where access would otherwise be delayed or limited. Our work spans infectious diseases, non-communicable diseases, maternal and child health, pandemic preparedness and emerging health technologies. Our non-exclusive, transparent licensing model supports competition, strengthens supply resilience and enables sustainable access over time, while recognising the role of innovation.

Contre-Feu is a French initiative focused on documenting and exposing the tobacco industry's lobbying efforts within the European Union by analyzing public registers and tracking meetings. The organization uses Freedom of Information requests to publish documents detailing interactions between the European Commission and tobacco interest groups to enhance political accountability. For more details, visit Contre-Feu.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. To learn more, please visit us on www.Pfizer.com and follow us Social Media.

The Hong Kong Convention and Exhibition Centre (HKCEC) is a striking waterfront venue in Wan Chai, known for its iconic glass structure and sweeping rooftop design. As one of Asia’s leading event spaces, it hosts major international exhibitions, conventions, and trade shows, offering over 91,000 square meters of space and stunning views of Victoria Harbour.